Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price traded up 5.1% on Thursday . The company traded as high as $6.23 and last traded at $6.02, with a volume of 323,003 shares. The stock had previously closed at $5.73.

A number of equities analysts have recently weighed in on the company. FBR & Co reiterated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. Wedbush reiterated a “neutral” rating and set a $4.00 target price on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. Zacks Investment Research lowered Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Cowen and Company reiterated a “buy” rating and set a $8.00 target price on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, April 17th. Finally, Leerink Swann restated an “outperform” rating and set a $11.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, April 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $11.00.

The firm’s 50 day moving average price is $5.58 and its 200 day moving average price is $4.72. The firm’s market cap is $516.95 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). During the same quarter in the previous year, the firm earned ($0.24) EPS. The business earned $27.47 million during the quarter, compared to analysts’ expectations of $27.17 million. Raptor Pharmaceutical Corp.’s quarterly revenue was up 34.3% on a year-over-year basis. On average, analysts expect that Raptor Pharmaceutical Corp. will post ($0.99) earnings per share for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 as of its most recent filing with the SEC.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.